The law firm is examining whether Immix Biopharma and certain officers or directors engaged in securities fraud after reports linked former Chief Medical Officer Richard Graydon to a fugitive arrested in July 2026.
Pomerantz LLP said it is investigating potential claims on behalf of investors in Immix Biopharma, Inc. over whether the company and certain officers or directors engaged in securities fraud or other unlawful business practices. The inquiry follows a sequence of disclosures involving former Chief Medical Officer Richard Graydon, whom Immix appointed on March 30, 2026 and said on July 20, 2026 had been terminated effective July 17, 2026 for reasons unrelated to his activities at the company. Media reports later cited a U.S. Marshals Service press release saying Graydon's real name was Ronald L. Fischer, who disappeared during his 2005 rape trial and remained a fugitive for more than 20 years until his arrest in July 2026 after a coordinated multi-state law enforcement operation. Immix shares fell $1.45, or 14.15%, to close at $8.80 on July 20, 2026. Pomerantz is asking investors to contact the firm about the matter.